International Journal of Medicine and Pharmaceutical Research
E-ISSN: 2321-2624 | https://doi.org/10.30904/j.ijmpr.2026.5001

An Investigation into the Opportunities and Challenges of Orphan Drug Regulations for Rare Diseases: A Comparative Policy and Evidence Synthesis

P. Eileen*, P. Laxmi, K Nagasree, K Shravan Kumar

Samskruti College of Pharmacy, Kondapur, Ghatkesar, Medchal, Hyderabad-501301, Telangana, India
***Corresponding E-Mail:** principal.y7@gmail.com*

Received: 16-03-2026 | Revised: 22-04-2026 | Accepted: 12-05-2026 | Published: 30-06-2026

ABSTRACT:
The analysis shows that orphan drug frameworks have substantially reshaped the pharmaceutical innovation landscape, delivering concrete opportunities: Incentive-driven R&D growth: Orphan incentives have clearly stimulated discovery and development in areas previously neglected. Pipeline data reveal an exponential increase in rare disease trials, particularly for genetic and ultra-rare conditions. These incentives have catalyzed the rise of biotech SMEs, which rely heavily on exclusivity protections and grant support to de-risk investment. Adaptive and expedited pathways: Regulatory innovations such as the U.S. Accelerated Approval, EU PRIME, and Japan's Sakigake designation have been effective in enabling earlier patient access. Crucially, these pathways can balance speed with responsibility when tied to robust post-marketing authorization (PMA) obligations, ensuring that uncertainty is progressively reduced. Infrastructure dividends: Investments in registries, natural history databases, and networks of centers of excellence have created public goods. These infrastructures not only enhance trial feasibility but also underpin real-world learning systems, contributing to better long-term outcome measurement and fostering international collaboration.
Keywords: Infrastructure dividends, EU PRIME, PMA, SMEs

1. Introduction

Rare diseases, often referred to as orphan diseases, encompass a broad spectrum of chronic, progressive, and frequently life-threatening conditions that collectively affect millions worldwide. While each condition is individually rare, estimates suggest that more than 7,000 rare diseases exist, cumulatively impacting between 6–8% of the global population. In Europe, a disease is considered rare if it affects fewer than 5 in 10,000 individuals; in the United States, the threshold is fewer than 200,000 affected individuals. Despite definitional differences, the underlying reality is universal: rare diseases impose a significant burden on patients, families, and health systems. Historically, these conditions remained neglected for several reasons. First, the market size for each orphan condition is small, limiting the commercial attractiveness of investing in research and development (R&D). Second, clinical trial design in small populations is scientifically challenging, with difficulties in recruiting adequate numbers of participants and establishing robust endpoints.

Third, the fixed costs of drug discovery, clinical testing, and regulatory approval are substantial, regardless of patient population size, creating an economic imbalance. Consequently, patients with rare diseases often faced limited or no therapeutic options, leading to unmet medical need and health inequity. To correct this market failure, several jurisdictions pioneered orphan drug frameworks, most notably the United States with the Orphan Drug Act of 1983, followed by the European Union in 2000, and Japan earlier in 1993. These frameworks introduced targeted incentives including market exclusivity, fee reductions or waivers, protocol assistance, tax credits, direct funding for clinical trials, and accelerated review procedures. Collectively, these measures transformed the rare-disease landscape, catalyzing exponential growth in orphan designations, approvals, and research activity. Nevertheless, the rapid success of these frameworks has triggered new debates. Orphan drugs frequently launch at extremely high prices, raising concerns about affordability and health-system sustainability. Some approvals are based on limited or uncertain evidence, reflecting the inherent challenges of small-population trials. Strategic industry practices such as subdividing common conditions into rare subgroups to qualify for orphan incentives—have raised questions about regulatory gaming. Moreover, global inequities persist, with low- and middle-income countries often lacking access despite globalized R&D. These tensions underscore the urgent need to revisit and refine orphan drug policies, ensuring that they deliver on their original promise while safeguarding value, fairness, and sustainability.

The Policy Problem

The central policy dilemma is one of balance: how can governments and regulators simultaneously stimulate R&D for neglected conditions and guarantee equitable, affordable access to effective therapies? On one hand, without strong incentives, companies are unlikely to invest in high-risk, low-return areas such as rare diseases. On the other, if incentives are too generous or insufficiently regulated, they may encourage inefficiencies, excessive pricing, or inequitable outcomes. This balancing act spans the entire drug lifecycle. In the pre-clinical stage, high uncertainty and limited basic science data hinder investment. In clinical development, small patient populations necessitate innovative trial designs, often requiring adaptive

methodologies, surrogate endpoints, or reliance on real-world data. At the regulatory approval stage, agencies face pressure to expedite access while ensuring safety and efficacy. In pricing and reimbursement negotiations, payers grapple with very high launch prices for drugs that target small patient groups, raising concerns about cost-effectiveness and budget impact. Post-market, the challenge shifts toward generating robust evidence on long-term effectiveness and safety, often under real-world conditions. Thus, the policy problem is not confined to a single node in the system but is systemic, requiring a lifecycle perspective that integrates innovation incentives, regulatory decision-making, payer policies, and patient outcomes.

2. Methodology

Study Design

This thesis adopts a mixed-methods design that combines comparative doctrinal and policy analysis, a scoping review of academic and grey literature, and explanatory case studies. This triangulated approach is chosen to capture the multidimensional nature of orphan drug regulation, which spans legal, regulatory, health policy, and economic perspectives.

- Comparative doctrinal/policy analysis enables systematic comparison of the legal and regulatory texts, highlighting variations across jurisdictions in eligibility, incentives, and regulatory pathways.
- Scoping review synthesizes peer-reviewed and grey literature to identify reported opportunities, challenges, and evolving evidence regarding orphan drug frameworks.
- Explanatory case studies illustrate how policies function in practice, tracing the lifecycle of specific products to examine real-world interactions among regulation, pricing, reimbursement, and access.

The integration of these three methods supports a holistic and evidence-informed evaluation, while also providing flexibility to capture both cross-jurisdictional patterns and product-specific experiences.

Eligibility and Selection of Jurisdictions

The analysis focuses on a set of jurisdictions selected through purposive sampling:

Established frameworks:

- **United States (USFDA)**: Pioneer of the Orphan Drug Act (1983).
- **European Union (EMA)**: Regulation (EC) No 141/2000.
- **Japan (PMDA/MHLW)**: One of the earliest adopters (1993).
- **Representative high-income and middle-income examples:**
- **Canada (Health Canada)**: Policy discussions ongoing; HTA relevance.
- **Australia (TGA)**: Smaller market with adapted regulatory pathways.
- **South Korea (MFDS)**: Emerging leader in Asia-Pacific rare disease policy.
- **India (CDSCO/NDCP)**: Illustrative of a middle-income country experimenting with rare disease policy frameworks.
- **Reliance/Work-sharing:**
- Jurisdictions leveraging international regulatory cooperation, such as Swissmedic (Switzerland) or joint EU–FDA scientific advice mechanisms.

This selection allows for comparative breadth (covering mature, emerging, and transitional systems) while also enabling depth of analysis in understanding diverse policy strategies.

Data Sources

Data are drawn from multiple sources, ensuring triangulation:

- **Legal and regulatory documents:** Statutes, regulations, guidance documents, consultation papers.
- **Regulatory databases:**
  - U.S.: FDA Orphan Drug Designations and Approvals database.
  - EU: EMA Orphan Designation Register.
  - Japan and others: National orphan drug designation lists.
- **Health Technology Assessment (HTA) and payer decisions:** NICE (UK), HAS (France), CADTH (Canada), PBAC (Australia).
- **Peer-reviewed publications:** Indexed in PubMed, Scopus, Web of Science.
- **Grey literature:** Policy reports, patient advocacy documents, think-tank analyses, industry white papers.

All data sources are systematically documented to enable replicability and transparency.

Scoping Review Protocol

The scoping review follows the Arksey & O'Malley (2005) and Joanna Briggs Institute (JBI) frameworks, adapted for policy-oriented research.

Review Question: What opportunities and challenges are reported in relation to orphan drug regulation, evidence standards, pricing, and patient access?

Search Strategy:

Combination of keywords such as *"orphan drug," "rare disease," "market exclusivity," "regulatory incentives," "HTA," "managed entry agreements."* Databases include PubMed, Embase, Scopus, Web of Science, and relevant grey literature portals.

Inclusion Criteria:

English-language publications.

- Last 10–15 years, with sentinel earlier studies included for historical grounding.
- Documents addressing regulatory, evidentiary, pricing, or access aspects.

Exclusion Criteria:

- Purely clinical or mechanistic studies without regulatory relevance.
- Commentaries lacking empirical or policy analysis.

Screening Process:

- Stage 1: Title/abstract screening.
- Stage 2: Full-text review using a standardized form.

Data Charting: Key fields extracted include jurisdiction, incentive type, evidentiary standards, pricing/HTA approaches, access outcomes, and thematic findings.

Comparative Policy Matrix Construction

A **comparative policy matrix** will be constructed to systematize cross-jurisdictional differences and similarities. Key variables include:

- **Eligibility criteria**: Prevalence thresholds, severity requirements, significant benefit clauses.
- **Incentives**: Exclusivity (duration/scope), fee waivers, scientific advice, tax incentives, grants.
- **Regulatory pathways**: Expedited review, conditional approval, adaptive licensing.
- **Post-market obligations**: RWE requirements, registries, risk management plans.
- **HTA and payer adaptations**: Modifiers, multi-criteria decision analysis, managed entry agreements.

Results

Jurisdictional Mapping

The comparative analysis reveals both convergence and divergence across jurisdictions in defining and incentivizing orphan medicines.

- **Finding 1:** All jurisdictions adopt a prevalence-based definition, though thresholds vary (U.S.: <200,000 individuals; EU: <5 in 10,000; Japan: <50,000). Some frameworks add qualitative requirements such as **"**significant benefit**"** (EU) or **"**lack of satisfactory therapy**"** (Canada proposals).
- **Finding 2:** Market exclusivity, fee reductions, and scientific advice are universal incentives. Fiscal incentives, however, vary: the U.S. provides generous R&D tax credits; Japan and South Korea offer government subsidies; the EU relies more on project-based research funding.
- **Finding 3:** Expedited or adaptive pathways (e.g., Accelerated Approval in the U.S., PRIME in the EU, Sakigake in Japan) are increasingly used for orphan approvals, reflecting regulatory willingness to trade evidentiary certainty for earlier access.

Evidence at Approval

The analysis of regulatory approvals highlights a distinctive **evidence profile** for orphan medicines.

- **Finding 4:** Orphan approvals are **disproportionately reliant on small trials,** often single-arm, with surrogate or biomarker endpoints. Median trial sizes are frequently <200 participants, reflecting inherent recruitment constraints.
- **Finding 5:** Regulators increasingly impose **post-marketing authorization (PMA) obligations** such as confirmatory RCTs, registry data, or long-term follow-up studies. However, evidence maturity at approval is uneven, and completion rates of PMA studies are inconsistent.



Figure 1: A. Evidence Maturity at Approval vs. PMA Obligations Timeline

Pricing, HTA, and Access

Orphan drug pricing and reimbursement remain highly contested arenas, with notable jurisdictional variation.

- **Finding 6:** HTA agencies frequently apply modifiers such as disease severity, unmet need, and rarity to justify approvals at higher cost-effectiveness thresholds. For instance, NICE (UK) uses an "end-of-life" and "highly specialized technology" modifier.
- **Finding 7: Access timelines** differ: the U.S. market offers rapid availability post-FDA approval, whereas EU member states vary widely (Germany: immediate launch; France/UK: delayed by HTA). Emerging economies face years-long delays.
- **Finding 8: Managed entry agreements (MEAs),** especially outcomes-based models, are increasingly adopted. Yet operational challenges remain: data infrastructure for real-world evidence (RWE) is weak, attribution of outcomes to drugs is contested, and small patient numbers introduce statistical noise.

Case Studies

Three case studies exemplify how orphan frameworks operate in practice.

Case A: Enzyme Replacement Therapy (ERT) – Gaucher Disease

- **Clinical Context**: Gaucher disease is a lysosomal storage disorder causing hepatosplenomegaly, anemia, and bone crises. Untreated, it is debilitating and life-threatening.
- **Study Design & Endpoints**: Initial approvals based on **open-label, non-randomized studies** measuring hematologic and organ volume endpoints.
- **Regulatory Route**: U.S. and EU orphan designation; granted market exclusivity.
- **HTA Decision**: NICE initially rejected ERT on cost-effectiveness grounds, later funded through special arrangements.
- **Post-Market Evidence**: Registry data confirmed clinical benefit but raised sustainability questions due to costs exceeding £200,000 per patient/year.
- **Access Equity**: Access remains highly unequal globally, limited in LMICs.

Case B: Small Molecule Therapy – Cystic Fibrosis Modulator

- **Clinical Context**:
  Cystic fibrosis, caused by CFTR gene mutations, historically had limited disease-modifying therapies.
- **Study Design & Endpoints**:
  Randomized trials in small subpopulations defined by genotype; **forced expiratory volume (FEV1)** as surrogate endpoint.
- **Regulatory Route**: Expedited approvals in the U.S. and EU.
- **HTA Decision**: NICE initially rejected due to affordability concerns; later negotiated through outcomes-based MEAs.
- **Post-Market Evidence**: Real-world studies confirmed significant clinical improvements, supporting reappraisal.

- **Access Equity**: Global roll-out slow; availability in LMICs remains limited.

Case C: Gene Therapy – Spinal Muscular Atrophy (SMA)

- **Clinical Context**: SMA is a severe neuromuscular disorder leading to early childhood mortality.
- **Study Design & Endpoints**: Single-arm trials (n<50) measuring **motor milestones.** No long-term durability data at approval.
- **Regulatory Route**: Orphan designation in U.S., EU, and Japan; expedited review.
- **HTA Decision**: Extremely high price (> $2 million per dose) sparked affordability crises. HTAs accepted under outcomes-based schemes.
- **Post-Market Evidence**: Ongoing registries and RWE collection; durability still under investigation.
- **Access Equity**: High-income countries have limited access through insurance/MEA schemes; LMIC access negligible.

Cross-Cutting Patterns

Synthesis across jurisdictions and case studies identifies key systemic patterns:

1. **Incentives and Time-to-Approval:** Jurisdictions with strong incentives and expedited pathways (e.g., U.S.) achieve faster approvals, but often at the cost of greater evidentiary uncertainty.
2. **PMA and HTA Reappraisals:** The presence (or absence) of robust post-market obligations strongly influences subsequent HTA decisions. Countries with structured registries (e.g., EU) show better ability to revisit cost-effectiveness.
3. **The Evidence–Price–Access Triangle:**
    - *Evidence constraints* drive reliance on surrogate endpoints and conditional approvals.
    - *High prices* exacerbate payer uncertainty, leading to MEAs.
    - *Access outcomes* remain uneven, particularly in resource-limited settings. This triangular tension defines the sustainability challenge of orphan drug regulation.

Discussion

Unpacking the Challenges

Despite successes, recurrent and systemic challenges remain.

- **Affordability**
  High launch prices often exceeding hundreds of thousands of dollars per patient annually—combined with long exclusivity periods create unsustainable pressures. The paradox is that even with small patient numbers, budget impact can be significant when prices are extreme or when cumulative orphan designations proliferate.
- **Evidence Uncertainty**
  Many orphan approvals rely on single-arm trials, surrogate endpoints, and limited patient numbers. While understandable, this introduces uncertainty at approval. Without rigorous PMA enforcement and data linkages to real-world evidence (RWE), uncertainty persists, undermining payer confidence and patient trust.
- **Strategic Behavior**
  Practices such as indication slicing (dividing broader diseases into rare subsets) and evergreening can lead to inefficient monopolies. If exclusivity incentives are not conditioned on value, firms may exploit frameworks without delivering proportional public health benefit.
- **Access Inequities**
  Geographic disparities remain stark. High-income countries secure relatively fast access, while patients in low- and middle-income countries (LMICs) face substantial delays or complete lack of availability. Pediatric populations and those with ultra-rare conditions are disproportionately underserved.



Figure 2: A. Value-Aligned Orphan Lifecycle Framework

Table 1: A. Stakeholder Roles in a Value-Aligned Framework

Stakeholder	Key Actions
Regulators	Enforce PMA, harmonize definitions, early advice
Payers/HTA	Apply explicit modifiers, outcomes-based contracts, re-pricing triggers
Industry	Plan beyond approval, co-design registries, transparency
Patients/Clinicians	Co-produce outcomes, advocate for access, engage in governance

Conclusion

Orphan drug regulations have transformed the therapeutic landscape for rare diseases. The adoption of the U.S. Orphan Drug Act in 1983 and subsequent diffusion of orphan frameworks to Europe, Japan, and beyond has stimulated unprecedented growth in rare disease R&D, catalyzed SME and biotech participation, and enabled earlier access for many patients who previously had no treatment options. These policies represent a landmark correction of market failure, demonstrating how targeted incentives can unlock innovation in neglected areas. Yet, the analysis in this thesis highlights that success has been accompanied by significant challenges. The combination of high prices, uncertain evidence at approval, and strategic behavior threatens affordability and sustainability. Inequities in global access particularly in low- and middle-income countries exacerbate disparities in health outcomes. Moreover, weak enforcement of post-marketing authorization

(PMA) obligations and limited integration of real-world evidence undermine long-term value demonstration. The core lesson is that orphan drug policy must move beyond a binary focus on incentives versus access. Instead, a lifecycle, value-aligned approach is required one that conditions incentives on verified outcomes, strengthens evidence development, and embeds collaboration and transparency as guiding principles. Such recalibration can sustain innovation while advancing fairness, affordability, and equity.

Funding
This study received no specific funding from public, commercial, or not for profit funding agencies.

AI Tool Declaration
The authors declare that no AI and related tools are used to write the scientific content of this manuscript.

Conflict of Interests
The authors declare no conflict of interest

Ethics Approval
Not applicable

Data Availability
Data will be available on request

References
[1] Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Kogej, T. (2018). Orphan drugs and rare diseases: A pharmaceutical industry perspective. *Drug Discovery Today, 23*(2), 273–281. https://doi.org/10.1016/j.drudis.2017.11.002

[2] Berman, J. J. (2020). *Rare diseases and orphan drugs: Keys to understanding and treating the common diseases*. Academic Press.

[3] Bertram, M., et al. (2017). Challenges in orphan drug regulation: A comparative analysis. *Health Policy, 121*(6), 564–571. https://doi.org/10.1016/j.healthpol.2017.03.006

[4] Braun, M. M., & Farag-El-Massah, S. (2019). Regulatory incentives for orphan drug development: A review. *Clinical Pharmacology & Therapeutics, 106*(3), 452–457. https://doi.org/10.1002/cpt.1420

[5] Canadian Agency for Drugs and Technologies in Health (CADTH). (2019). *Drugs for rare diseases: CADTH perspective*. CADTH Report.

[6] Cote, T. R., & Keating, K. A. (2012). The Orphan Drug Act and rare disease drug development. *Clinical Therapeutics, 34*(11), 2396–2404. https://doi.org/10.1016 /j.clinthera.2012.09.021

[7] Drummond, M., & Towse, A. (2014). Orphan drugs policies: A suitable case for treatment. *European Journal of Health Economics, 15*(4), 335–340. https://doi.org/10.1007/s10198-013-0488-6

[8] European Medicines Agency (EMA). (2020). *Orphan designation: Overview*. https://www.ema.europa.eu

[9] EURORDIS. (2017). *Breaking the access deadlock to leave no one behind*. EURORDIS Position Paper.

[10] Gammie, T., Lu, C. Y., & Babar, Z. U. (2015). Access to orphan drugs: A comprehensive review of legislations, regulations and policies in 35 countries. *PLoS ONE, 10*(10), e0140002. https://doi.org/ 10.1371/journal.pone.0140002

[11] Global Genes. (2021). *Rare disease impact report*. Global Genes Report.

[12] Hughes-Wilson, W., Palma, A., Schuurman, A., & Simoens, S. (2012). Paying for the orphan drug system: Break or bend? *Orphanet Journal of Rare Diseases, 7*(1), 74. https://doi.org/10.1186/1750-1172-7-74

[13] Joppi, R., Bertele, V., & Garattini, S. (2013). Orphan drugs, orphan diseases: The first decade of orphan drug legislation in the EU. *European Journal of Clinical Pharmacology, 69*(5), 1009–1024. https://doi.org/10.1007/s00228-012-1423-2

[14] Kakkar, A. K., & Dahiya, N. (2014). The evolving regulatory framework for orphan drugs in India. *Perspectives in Clinical Research, 5*(3), 130–134. https://doi.org/10.4103/2229-3485.134304

[15] Kesselheim, A. S., Myers, J. A., & Avorn, J. (2011). Characteristics of clinical trials to support approval of orphan vs. nonorphan drugs for cancer. *JAMA, 305*(22), 2320–2326. https://doi.org/ 10.1001/jama.2011.769

[16] McCabe, C., Claxton, K., & Tsuchiya, A. (2005). Orphan drugs and the NHS: Should we value rarity? *BMJ, 331*(7523), 1016–1019. https://doi.org/10.1136/bmj.331.7523.1016

[17] Milne, C. P., & Bruss, J. B. (2008). The economics of pediatric orphan drug development. *Expert Opinion on Orphan Drugs, 2*(9), 869–875. https://doi.org/10.1517/21678707.2014.949233

[18] National Organization for Rare Disorders (NORD). (2020). *The state of rare disease drug development in the U.S.* NORD Report.

[19] Nicod, E., Kanavos, P., & van den Aardweg, S. (2019). HTA for rare diseases: Approaches in Europe. *Value in Health, 22*(5), 518–526. https://doi.org/10.1016/j.jval.2019.01.008

[20] Orphanet. (2021). *Orphanet Report Series: Rare Disease Registries*. Orphanet.

[21] Picavet, E., Cassiman, D., & Simoens, S. (2012). Orphan drugs: Expensive yet necessary. *Pharmacoeconomics, 30*(7), 537–542. https://doi.org/10.2165/11598000-000000000-00000

[22] Rawson, N. S. B. (2017). Review of access and reimbursement decisions for new medicines in Canada. *Canadian Health Policy Institute Report*.

[23] Richter, T., Nestler-Parr, S., Babela, R., Khan, Z. M., Tesoro, T., Molsen, E., & Hughes, D. A. (2015). Rare disease terminology and definitions—A systematic global review. *Value in Health, 18*(6), 906–914. https://doi.org/10.1016/j.jval.2015.05.008

[24] Sarnola, K., et al. (2020). Managed entry agreements for medicines in Europe: Analysis of country approaches. *Health Policy, 124*(5), 512–518. https://doi.org/10.1016/j.healthpol.2020.03.004

[25] Simoens, S., & Picavet, E. (2021). Improving access to orphan drugs for rare diseases in the European Union. *Orphanet Journal of Rare Diseases, 16*(1), 50. https://doi.org/10.1186/s13023-021-01706-w

[26] Tambuyzer, E., et al. (2020). Therapies for rare diseases: Therapeutic modalities, progress, and challenges ahead. *Nature Reviews Drug Discovery, 19*(2), 93–111. https://doi.org/10.1038/s41573-019-0049-9

[27] U.S. Food and Drug Administration (FDA). (2021). *Developing products for rare diseases & conditions*. FDA Guidance.

[28] van den Haak, P., et al. (2022). Global perspectives on orphan drug access and policy. *Frontiers in Pharmacology, 13*, 835647. https://doi.org/10.3389/fphar.2022.835647

[29] Wästfelt, M., Fadeel, B., & Henter, J. I. (2006). A journey of hope: Lessons learned from studies on rare diseases and orphan drugs. *Journal of Internal Medicine, 260*(1), 1–10. https://doi.org/10.1111/j.1365-2796.2006.01666.x